Search

Your search keyword '"Bron D"' showing total 63 results

Search Constraints

Start Over You searched for: Author "Bron D" Remove constraint Author: "Bron D" Database OAIster Remove constraint Database: OAIster
63 results on '"Bron D"'

Search Results

1. Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation

2. Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation

3. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study.

4. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study.

5. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

6. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

7. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

8. Adherence to geriatric assessment-based recommendations in older patients with cancer: a multicenter prospective cohort study in Belgium.

9. Determining clinically important differences in health-related quality of life in older patients with cancer undergoing chemotherapy or surgery.

10. Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study

11. Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study

12. Waldenström’s macroglobulinaemia : Belgian Hematology Society guidelines

13. BHS Guidelines for the treatment of Burkitt’s lymphoma

14. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia.

15. Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013)

16. Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013)

17. Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013)

18. High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial

19. Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT

20. High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial

21. Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT

22. High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial

23. Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT

24. High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial

25. SAR245409 monotherapy in relapsed/refractory follicular lymphoma: Preliminary results from the phase II ARD12130 study.

26. Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: A randomised phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)

27. Relevance of a systematic geriatric screening and assessment in older patients with cancer: Results of a prospective multicentric study

28. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: A retrospective study from the European Group for Blood and Marrow Transplantation

29. SAR245409 monotherapy in relapsed/refractory follicular lymphoma: Preliminary results from the phase II ARD12130 study.

30. EORTC Leukemia Group Achievements

31. Guidelines of the Belgian hamatological Society for newly diagnosed and relapsed follicular lymphoma 2012.

32. BHS guidelines for the treatment of chronic lymphocytic leukaemia anno 2012

33. EORTC Leukemia Group Achievements

34. Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group.

35. Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group.

36. Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group.

37. A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies

38. Microrna-29c and 223 and Their Prognostic Value in Chronic Lymphocytic Leukemia

39. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP.

40. Stem cell transplantation in ALL: a donor versus no donor comparison in the EORTC ALL-4 study.

41. Palifermin treatment in patients receiving high dose melphalan or beam prior to autologous peripheral blood stem-cell transplantation

42. Fludarabine phosphate-based reduced intensity conditioning for allogeneic stem cell transplantation in patients with acute myeloid leukemia, myelodysplasia and chronic myeloid leukemia: Update of a national dose-finding study

43. Stem cell transplantation in ALL: a donor versus no donor comparison in the EORTC ALL-4 study.

44. Stem cell transplantation in ALL: a donor versus no donor comparison in the EORTC ALL-4 study.

45. Palifermin treatment in patients receiving high dose melphalan or BEAM prior to autologous peripheral blood stem-cell transplantation.

46. Late non-neoplastic events in patients with aggressive non-Hodgkin's lymphoma in four randomized European Organisation for Research and Treatment of Cancer trials.

47. Stem cell transplantation from identical twins in patients with myelodysplastic syndromes.

48. Comparison of proposed diagnostic criteria with FACT-F and VAS for cancer-related fatigue: proposal for use as a screening tool

49. The role of GM-CSF in adult haplo-identical tranplant who cannot benefit from NK allo-reactivity

50. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: A retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT)

Catalog

Books, media, physical & digital resources